First Clinical Cases of OXA-48-Producing Carbapenem-Resistant Klebsiella pneumoniae in the United States: the “Menace” Arrives in the New World | Zendy

Amy J. Mathers | Zendy; Kevin C. Hazen | Zendy; Joanne Carroll | Zendy; Anthony J. Yeh | Zendy; Heather L. Cox | Zendy; Robert A. Bonomo | Zendy; Costi D. Sifri | Zendy

Open Access

First Clinical Cases of OXA-48-Producing Carbapenem-Resistant Klebsiella pneumoniae in the United States: the “Menace” Arrives in the New World

Author(s) -

Amy J. Mathers,

Kevin C. Hazen,

Joanne Carroll,

Anthony J. Yeh,

Heather L. Cox,

Robert A. Bonomo,

Costi D. Sifri

Publication year - 2012

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.02580-12

Subject(s) - enterobacteriaceae , klebsiella pneumoniae , carbapenem resistant enterobacteriaceae , microbiology and biotechnology , klebsiella infections , enterobacteriaceae infections , biology , klebsiella , carbapenem , medicine , virology , antibiotics , escherichia coli , gene , genetics

OXA-48 has emerged as a major carbapenemase associated with theEnterobacteriaceae in Europe, North Africa, and Asia. We report the first two clinical cases of OXA-48-type carbapenemase-producingEnterobacteriaceae in the United States from patients recently hospitalized in Saudi Arabia and India. Each is more carbapenem resistant than nearly all previously reported OXA-48-type-producingEnterobacteriaceae .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research